TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first oral resolution film (ODF) of apixaban. Th...
Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) ...
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administe...
Pfizer Inc. announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)...
WALTHAM, Mass. Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Invitrogen™ EVOS™ S1000 Spatial Imaging Syste...
The €50+ million investment will enhance Axplora CDMO’s Mourenx site with state-of-the-art facilities and infrastructure improvements. Axpl...
Novartis announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceut...
Global biotechnology leader CSL announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one...
Regeneron Pharmaceuticals, Inc.announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (afliber...
The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal ...
Valneva SE , a specialty vaccine company, announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing author...
Zoetis Inc. announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission of a supplement to the U.S...
Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced that it is col...
AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults ...
© 2025 Biopharma Boardroom. All Rights Reserved.
